BiotechTube
Home/Pipeline/TW002

TW002

Not Specified

Not SpecifiedActive

Key Facts

Indication
Not Specified
Phase
Not Specified
Status
Active
Company
Treeway

About Treeway

Treeway is a patient-founded, Netherlands-based biotech focused on the formidable challenge of treating neurodegenerative diseases like ALS and Alzheimer's. Its lead asset, TW001, is an oral formulation of edaravone being developed for Alzheimer's disease, with Phase 2 results recently accepted for a late-breaking presentation. The company operates with a lean, expert team and leverages strategic academic and industry collaborations to advance its preclinical and clinical pipeline.

View full company profile

Therapeutic Areas

Amyotrophic Lateral Sclerosis (ALS)Alzheimer's DiseaseNeurodegenerative Diseases

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved